从恩替卡韦转换为替诺福韦艾拉酚胺与维持恩替卡韦治疗慢

StephenW

J Med Virol. 2019 Jun 14. doi: 10.1002/jmv.25515. [Epub ahead of print]
Switching from Entecavir to Tenofovir alafenamide versus maintaining Entecavir for chronic hepatitis B.
Hagiwara S1, Nishida N1, Ida H1, Ueshima K1, Minami Y1, Takita M1, Komeda Y1, Kudo M1.
Author information

1
    Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Osaka-, Sayama, Japan.

Abstract

Tenofovir alafenamide (TAF) is a newly developed prodrug of tenofovir (TFV). We divided 48 CHB patients who had taken ETV for ≥2 years into two groups: the ETV continuation (n=24) and the TAF switching (n=24) groups, and compared the antiviral effects and safety until 48 weeks after the start of study. There were no significant differences in the alterations in the serum levels of HBs antigen (HBsAg) level between the ETV continuation and the TAF switching groups at 24 or 48 weeks. We also examined the effect of baseline HBsAg level on the decrease of HBsAg during the treatment; in the TAF switching group, the decrease of HBsAg level at 48 weeks was more significant in patients with low baseline HBsAg (< 800 IU/ml) than those with high baseline HBsAg (> 800 IU/ml) (change of HBsAg; -0.029 vs -0.132 for high and low baseline HBsAg, respectively, p = 0.007). Also, the effect on renal function was found to be comparable between the TAF switch group and the ETV continuation group. In this study, switching from ETV to TAF may represent higher efficacy for decrease of HBsAg than continuation of ETV among the patients with low baseline HBsAg level. This article is protected by copyright. All rights reserved.

This article is protected by copyright. All rights reserved.
KEYWORDS:

Hepatitis B virus; N-acetyl-β-D-glucosaminidase; entecavir hydrate; tenofovir alafenamide fumarate; tenofovir disoproxil fumarate

PMID:
    31199513
DOI:
    10.1002/jmv.25515

StephenW

J Med Virol。 2019年6月14日doi：10.1002 / jmv.25515。 [印刷前的电子版]
从恩替卡韦转换为替诺福韦艾拉酚胺与维持恩替卡韦治疗慢性乙型肝炎。
Hagiwara S1，Nishida N1，Ida H1，Ueshima K1，Minami Y1，Takita M1，Komeda Y1，Kudo M1。
作者信息

1
    日本狭山大阪金达大学医学院消化内科和肝病学系。

抽象

替诺福韦艾拉酚胺（TAF）是新开发的替诺福韦（TFV）前药。我们将服用ETV≥2年的48例CHB患者分为两组：ETV持续（n = 24）和TAF转换（n = 24）组，并比较抗病毒效果和安全性，直至开始后48周。研究。在24或48周时，ETV持续时间和TAF转换组之间血清HBs抗原（HBsAg）水平的变化没有显着差异。我们还检查了基线HBsAg水平对治疗期间HBsAg降低的影响;在TAF转换组中，基线HBsAg（<800 IU / ml）低于基线HBsAg（> 800 IU / ml）的患者48周时HBsAg水平降低更为显着（HBsAg变化; -0.029）对于高和低基线HBsAg，分别为-0.132，p = 0.007）。此外，发现TAF开关组和ETV持续组之间对肾功能的影响是相当的。在这项研究中，从ETV转为TAF可能代表HBsAg降低的疗效高于基线HBsAg水平低的患者的ETV持续率。本文受版权保护。版权所有。

本文受版权保护。版权所有。
关键词：

乙型肝炎病毒; N-乙酰基β-d氨基葡萄糖苷酶;恩替卡韦水合物;替诺福韦艾拉酚酰胺富马酸盐;替诺福韦地索普西富马酸盐

结论：
    31199513
DOI：
    10.1002 / jmv.25515

齐欢畅

taf更优

yyjj777

这个是怎么翻的？google?

StephenW

回复 yyjj777 的帖子

是的，谷歌翻译.